Welcome and introduction (ID 6050)
New data and updated expectations for 1L therapy (ID 6051)
Managing AEs and keeping patients on treatment (ID 6052)
What next? Options after progression on 2nd and 3rd generation TKIs (ID 6053)
The future of ALK+ NSCLC (ID 6054)
Summary and close (ID 6603)
